Ax-1 is headed back to Earth after 12 days of research on the ISS. Photo courtesy of SpaceX

Editor's note: Undocking was delayed again on April 19, and a new timeline has not been announced. The original story is below.

After spending 12 days in space, a historic commercial space mission will splash back down on Earth this week.

Houston-based Axiom Space’s first mission Axiom mission 1 (Ax-1), which took off April 8 and connected to the International Space Station, has announced its plans for undocking and splashdown.

After some initial bad weather postponed the process, the four-member private astronaut crew now is aiming to undock at about 9 pm tonight, April 19, and then land off the coast of Florida at around 2:24 pm tomorrow, April 20. Just like launch, the coverage of both events will be available at Axiom's website.

The mission on SpaceX’s spacecraft sent four multinational private astronauts — Commander Michael López-Alegría, Pilot Larry Connor, Mission Specialist Eytan Stibbe, and Mission Specialist Mark Pathy — to the ISS to conduct research and familiarize Axiom with launch, docking, and more.

Axiom Space, which reached $1 billion valuation and joined the Houston unicorn club last year after a $130 million investment round, is working on the first commercial space station to replace the ISS. The first launch of that mission is expected in late 2024. In the meantime, Axiom has a series of commercial launches to the existing station currently in orbit in order to prepare for development and orchestration of Axiom Station.

The Ax-1 mission, which has provided daily updates, has conducted over 20 research projects and even hit a few milestones, including:

  • The first-ever music duet performance in space — Commander López-Alegría and Neo-Classical Piano Prodigy BLKBOK made music and space history with their piano and keyboard duet
  • The Aging and Heart Health investigation, an experiment from the Mayo Clinic — a study that analyzes human cells for genetic markers of cellular aging and explores cardiac-like cells' adaptation to microgravity
  • Observation of Transient Luminous Events — Specialist Stibbe completed a space observation experiment and photographed a lightning storm over Darwin, Australia, to enhance understanding of the electrical processes in the atmosphere and to determine whether there’s a connection with climate change
  • Testing of the Holoportation system — Mission Specialist Pathy set up two-way AI technology that will allow the ability of future crew members to explore deep space with the ability to virtually bring friends, family, and physicians close with them so that they can get an on-Earth experience
  • Several outreach calls to Earth to STEM students from around the world — this included a call to children at Space Center Houston

Axiom shares more details on its mission research projects — which span technologies such as future space habitats, cancer research, and devices to purify air on space stations — online.

“As the first step on a path to building a diverse, thriving economy in low-Earth orbit, Axiom has partnered with leaders in academia and industry to bring new users and new investigations in research to the space station,” says Christian Maender, director of In-space Manufacturing and Research for Axiom Space, in a news release. “The collection of biological and technological tests during the Ax-1 mission represent a breadth of research that will inform everything from human health considerations to novel infrastructure and design for our future homes away from Earth, beginning with Axiom Station.”

The four-person crew spent 12 days on the ISS. Photo courtesy of NASA

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."